A double-blind, randomized, placebo-controlled, phase III trial has shown that ripretinib (a switch-control tyrosine kinase inhibitor) markedly improves progression-free survival in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. From across 29 specialized hospitals in 12 locations, 129 patients (>18 years old) were recruited and randomly assigned to receive either oral ripretinib 150 mg once daily (n = 85) or placebo once daily (n = 44). In the double-blind period, median progression-free survival was 6.3 months (95% CI 4.6–6.9) in the ripretinib group versus 1.0 month (95% CI 0.9–1.7) in the placebo group (hazard ratio 0.15, 95% CI 0.09–0.25; P < 0.0001). Ripretinib had an acceptable safety profile, with the most common grade 3 or 4 treatment-emergent adverse events including, among others, hypertension and fatigue in the ripretinib group.
References
Original article
Blay, J.-Y. et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30168-6 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ray, K. Ripretinib for advanced gastrointestinal stromal tumours. Nat Rev Gastroenterol Hepatol 17, 452 (2020). https://doi.org/10.1038/s41575-020-0336-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-020-0336-2